Frontier Medicines Adds Kevin Webster, Johannes Hermann to C-Suite

Frontier Medicines has appointed Kevin Webster to serve as the cancer drug developer’s chief scientific officer. Webster most recently worked at eFFECTOR Therapeutics as its senior vice president of cancer biology. Frontier also named Johannes Hermann its chief technology officer. Hermann was most recently senior director and global head for data sciences at Johnson & Johnson (NYSE: [[ticker:JNJ]]). South San Francisco-based Frontier launched in June backed by $67 million in Series A financing.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.